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Regulatory T cells (Treg) have been shown to play a role in the prevention of autoimmune
diseases and transplant rejection. Based on an established protocol known to generate
alloantigen reactive Treg in vivo, we have developed a strategy for the in vitro selection of
Treg. Stimulation of unfractionated CD4
+ T cells from naive CBA.Ca (H2
k) mice with C57BL/
10 (H2
b) splenocytes in the presence of an anti-CD4 antibody, YTS 177, resulted in the
selection of Treg able to inhibit proliferation of naive T cells. In vivo, the cells were able to
prevent rejection of 80% C57BL/10 skin grafts when co-transferred to CBA.Rag
–/– mice
together with naive CD45RB
highCD4
+ cells. Purification of CD62L
+CD25
+CD4
+ cells from the
cultures enriched for cells with regulatory activity; as now 100% survival of C57BL/10 skin
graftswasachieved.Furthermore, differentiation ofTregcould bealsoachievedwhenusing
purified CD25
–CD4
+ naive T cells as a starting population. Interestingly, further in vitro
expansion resulted in a partial loss of CD4
+ cells expressing both CD62L and CD25 and
abrogation of their regulatoryactivityinvivo. This study shows that alloantigen stimulation
in the presence of anti-CD4 in vitro provides a simple and effective strategy to generate
alloreactive Treg.
Key words: Anti-CD4  IFN-c  Transplantation  Treg
Introduction
Naturally occurring regulatory Tcells (nTreg) are produced in the
thymus during normal Tcell development [1] and are involved in
the maintenance of self-tolerance [2–5] and development of
tolerance to allogeneic transplants [6–8]. Despite its broad
spectrum of reactivity, the frequency of nTreg responding to
foreign antigens is low and unable to provide protection against
grafts mismatched for multiple major and minor histocompat-
ibility antigens following transplantation [9,10]. On the contrary,
Treg induced in response to antigen (iTreg) are generated from
naive T cells under defined conditions in vivo and in vitro [2,
11–19]. For therapeutic purposes, it may be possible to harness
both the potential of nTreg as well as to generate T cells with
regulatory activity to defined antigens, such as alloantigens, ex
vivo. Repeated stimulation of unfractionated CD4
+ cells in the
presence of IL-10 or using a combination of immunosuppressive
drugs induces the selection of Treg invitro. These induced Treg are
able to prevent colitis or central nervous system inflammation in
animal models [20–22].
Pre-treatment of naive CBA mice with a non-depleting anti-
CD4 mAb (YTS 177) and donor-specific (B10) transfusion enables
the development of alloantigen-reactive CD4
+ Treg, which render
the recipient tolerant to a subsequent challenge with an allogeneic
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e-mail: birgit.sawitzki@charite.decardiac allograft [16, 23–25]. The transplant provides a source of
donor alloantigen indispensable for the persistence of the
regulatory cells in vivo [26]. In this study, we have addressed
whether a similar strategy can be used in vitrotoselect and expand
CD4
+ Treg. We show that alloantigen stimulation of total CD4
+ or
CD25
–CD4
+ naive cells in the presence of a non-depleting anti-
CD4antibody(YTS177)drivestheselectionofapopulationofTreg
that express CD25, CD62L, CCR7 and Foxp3 and are capable of
suppressing the proliferation and cytokine expression of naive
responder Tcells, in vitro. Most importantly, these Treg are able to
prevent the rejection of an allogeneic skin graft mediated by
CD45RB
highCD4
+ cells when co-transferred into CBA.Rag
–/–
recipients. Interestingly, expansion of the in vitro selected CD4
+
cells with regulatory activity in the presence of IL-2 resulted in a
lossof theircapacity topreventallograftrejectioninvivo, although
they retained their suppressive properties in vitro. This in vitro
approach provides a complementary strategy toin vivoselection of
Treg for controlling rejection and illustrates the tolerogenic
potential of non-depleting anti-CD4 antibodies.
Results
Alloantigen stimulation in the presence of anti-CD4
antibody selects CD4
+ cells with regulatory properties
in vitro and in vivo
Here, we asked whether in vitro blockade of CD4 signals toTcells
at the time of alloantigen recognition, i.e. in the presence of
allogeneic APC, would result in the selection of a population of
CD4
+ cells with suppressive properties. Purified, unfractionated
CD4
+ cells from naive CBA mice were cultured with irradiated,
allogeneic splenocytes from B10 mice in the presence of 5 lg/mL
anti-CD4. After 8 days in culture, their suppressive properties
were investigated by coculturing the cells with naive, syngeneic
CD4
+ cells in the presence of allogeneic B10 splenocytes. As
illustrated in Fig. 1A, CD4
+ naive T cell responders failed to
proliferate when cocultured with CD4
+ cells precultured with
anti-CD4 (CD4
pres). At this ratio, CD4
+ cells precultured without
anti-CD4 (CD4
abs) can also inhibit the proliferation of naive
responders, demonstrating that CD4
pres or CD4
abs could suppress
the proliferation of naive CD4
+ responders in vitro. Differences
between these two populations are detected at lower ratios (1:20)
whenCD4
absloosetheir potentialtosuppressproliferation.Invitro
suppression by CD4
pres may result from its ability to inhibit IL-2
and IFN-c production by naive CD4
+ cells (data not shown),
however other mechanisms may be involved as CD4
pres express
and secrete IL-10 and IFN-c (data not shown).
Next, we tested whether CD4
pres have lost their potential to act
as effector Tcells, i.e. the ability to initiate rejection. CD4
pres (2 
10
5) or the same number of CD4
abs (control culture) were
adoptively transferred into CBA.Rag
–/– mice and the following day
a B10 skin allograft was transplanted. Six out of seven mice
reconstituted with CD4
pres accepted their skin grafts (n =7 ,
median survival time (MST) >100 days, Fig. 1B), whereas three
outof fivemice reconstituted with CD4
abs rejected their skin grafts
acutely (n = 5, MST = 24 days, p>0.05, Fig. 1B). Statistically,
when compared to CBA.Rag
–/– mice reconstituted with
CD45RB
highCD4
+ naive cells, both CD4
pres and CD4
abs have lost
their potential to act as effector Tcells in vivo. To assess the in vivo
regulatory potential of the cultured CD4
+ cells, CBA.Rag
–/– mice
were reconstituted with 10
5 CD45RB
highCD4
+ naive T cells and
210
5CD4
presorCD4
abs.CD4
prespreventedrejection insevenout
of nine mice (n = 9, MST >100 days, p<0.0001 vs. MR), whereas
most mice co-reconstituted with CD4
abs cells rejected the graft
(n = 6, MST = 31 days, p<0.04 vs. 2  10
5 CD4
pres) (Fig. 1C).
From these results we can conclude that the presence of anti-CD4
during in vitro culture enhances the regulatory capacity of CD4
+
cells. Next, the minimum cell number to achieve in vivo regulation
was determined. Therefore, varying cell numbers of CD4
pres were
co-transferred with 10
5 CD45RB
highCD4
+ naive T cells into
CBA.Rag
–/– mice the day before transplantation of a B10 skin
graft. Co-transfer of 2  10
5 CD4
pres led to permanent acceptance
of B10 skin grafts in four out of six mice (n = 6, MST = 94 days,
p<0.05 vs. MR, Fig. 1D). Interestingly, transfer of 10
5 or 5  10
4
CD4
pres could still prevent rejection in a proportion of recipients
(n = 5, MST = 49 days; n = 5, MST = 57.6 days, respectively.
Fig. 1D). These results indicate that although both CD4
abs and
CD4
pres are unable to induce graft rejection in the absence of an
effector population, only CD4
pres can regulate skin graft rejection
mediated by CD45RB
highCD4
+ cells in vivo.
CD4
pres exhibit antigen specificity
It has been shown that regulatory T cells require activation
through Tcell receptor in order to manifest functional activity but
thereafter are nonspecific, i.e. once these cells are activated [27,
28]. Therefore, we wanted to test whether Tcells with regulatory
activity, CD4
pres, could suppress the proliferation of naiveTcells in
an antigen specific or nonspecific fashion. CD4
pres were cultured
with CD4
+ cells from naive mice in the presence of either B10 or
BALB/c allogeneic APC (Fig. 2A). Differential suppression,
twofold, of responses to B10 or BALB/c stimulation was only
detectable at very low ratios,1:20 (Fig. 2A). These results showed
that the response to third party antigen is not suppressed by
CD4
pres to the same extent as the response to cognate antigen.
Similar results were recently reported by Yamazaki et al. [29].
Next,we investigated the specificityof regulation byCD4
pres in
vivo. CD4
pres precultured in the presence of B10 APC were unable
to prevent the rejection of a BALB/c skin graft (n = 6, MST =
26.3 days, BALB/c skin grafts, vs. n = 6, MST = 94 days, B10 skin
grafts; p<0.05, Fig. 2B). Rejection of third party BALB/c skin graft
in mice co-transferred with CD4
pres and CD45RB
highCD4
+ cells
was not significantly different from rejection in mice reconstituted
with CD45RB
highCD4
+ cells alone (n = 5, MST = 23.4 days,
p = 0.08, Fig. 2B). Hence, CD4
pres can suppress the proliferation
of naive responders to third party stimulation in vitro but are
unable to prevent the rejection of a third party skin graft
in vivo.
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pres can be expanded further in vitro but lose
regulatory activity
Recently, studies by several groups have suggested that regulatory
T cells can be expanded in vitro without loss of function using
typical T cell growth factors such as IL-2 and IL-15 [30, 31]. The
percentage of cell recovery of CD4
+ cells after 8 days in culture in
the presence of B10 APC and anti-CD4 is around 30% of the
starting population (Fig. 3A). Therefore, we tested whether the
population of CD4
pres could be expanded. After 8 days in culture
with anti-CD4, CD4
+ cells were restimulated with allogeneic
splenocytes (B10) for a further 7 days in the presence of
exogenous IL-2 (25 U/mL). Indeed, the addition of IL-2 resulted
in an eightfold increase in the number of cells recovered from the
cultures and the potential of the expanded CD4
pres to prevent
proliferation of naive CD4
+ cells in vitro was not diminished
(Fig. 3B). Furthermore, suppression was still as potent at very low
ratios such as 1:50 (8.3% proliferation at 1:50 vs. 9.1% at 1:1,
Fig. 3B). In contrast to the non-expanded anti-CD4 Treg, as few as
4000 expanded CD4
pres were now sufficient to prevent prolifera-
tion of naive CD4
+ cells.
Next,we investigated whether the expanded CD4
pres wereable
to prevent skin graft rejection in vivo. All mice reconstituted with
CD45RB
highCD4
+ cells alone rejected their skin grafts acutely
grafts (n = 8, MST = 14 days, Fig. 3C). Co-transfer of expanded
CD4
pres could not prevent skin graft rejection although rejection
Figure 1. Influence of CD4
pres and CD4
abs on proliferation of naive T cells and skin graft rejection. (A) CD4
+ cells precultured in vitro for 8 days with
5 lg/ml of anti-CD4 (YTS 177) (CD4
pres) or without anti-CD4 antibody (CD4
abs) were cultured with CD4
+ responder T cells (2  10
5) from naive CBA
mice and irradiated allogeneic B10 splenocytes (5  10
5). Proliferation was measured at day 5 by
3H-thymidine incorporation. Data are expressed as
mean cpm + SD of triplicate cultures. The resultsshownarerepresentativeof four independent experiments. (B) CBA.Rag
–/– micewere reconstituted
with 2  10
5 CD4
pres (*; n = 7) or CD4
abs (&, n = 5). The next day mice received an allogeneic skin graft from B10 mice. Results were pooled from two
independent experiments. (C) CBA.Rag
–/– mice were reconstituted with 10
5 CD45RB
highCD4
+ effector T cells from naive animals (control = MR mice;
&, n = 9) or together with 2  10
5 CD4
pres (*; n =9 )o rC D 4
abs (~; n = 9). Results were pooled from five independent experiments. (D) CBA.Rag
–/– mice
were reconstituted with 10
5 CD45RB
highCD4
+ effector T cells from naive animals (control = MR mice; &, n = 7) or together with 2  10
5 (*; n =6 ) ,
10
5 (~; n =5 )o r5 10
4 CD4
pres (*
; n =5 ) .
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Fig. 3C). These results indicate that although the expanded
CD4
pres show a high regulatory potential in vitro, they were unable
to prevent skin graft rejection in vivo.
Cells with highest regulatory potential are present
within the CD62L
+CD25
+ CD4
+ subpopulation
Lymphocyte extravasation from the blood circulation into high
endothelial venules and subsequent entry into the secondary
lymphoid organs involves a series of step-wise events, which
involve CD62L and CCR7 [32]. The mAb, which block the
interaction of CD62L with its ligands, prevent indefinite allograft
survival and highlight the importance of this molecule for
alloantigen tolerance [33]. To understand the differences in
regulatory potential in vivo between expanded and non-expanded
CD4
pres, the profile of cell-surface expression of both T cell
populations was analysed. Cells were harvested after 8 days in
culture(non-expandedCD4
pres)orafterafurther7 daysinculture
in the presence of IL-2 (expanded CD4
pres) and stained with
antibodies recognising CD62L and CD25. Of all non-expanded
CD4
pres, 36% expressed both CD25 and CD62L, whereas only 11%
of the expanded population could be stained with both antibodies
(Fig. 4A). These findings together with published studies from
other groups [34–37] prompted us to investigate if this difference
in CD62L expression could explain the results obtained in vivo
(Fig. 1C and 3C). We analysed CD62L expression in CD25
+CD4
+
cells from CD4
pres and CD4
abs and found that 83 and 68% of cells,
respectively, expressed CD62L. This surface marker is known to be
necessaryforcells tomigrate inandoutof lymphnodes.Following
this observation, we decided to study CCR7 expression in
CD25
+CD4
+ cells from CD4
pres and CD4
abs and found that,
whereas58% ofCD25
+CD4
+cells fromCD4
pres express CCR7,this
percentage decreased to 17% in CD25
+CD4
+ cells from CD4
abs
(Fig. 4B).
Based on these observations, we investigated whether
CD62L
+CD25
+CD4
+ cells purified from CD4
pres or CD4
abs showed
regulatory activity in vivo. Cells were separated by cell sorting into
three cell populations according to their surface expression of
CD25 and CD62L: CD62L
+CD25
+, CD62L
–CD25
int and
CD62L
+CD25
– (Fig. 5A). CBA.Rag
–/– mice were reconstituted
with 10
5 CD45RB
highCD4
+ cells either alone or together with 2 
10
5 of each purified population from CD4
pres or CD4
abs (Fig. 5B).
The following day, mice received a B10 skin allograft. In vivo
regulatory properties resided in the CD62L
+CD25
+CD4
+ popula-
tion, regardless of their previous culture with (n = 11, MST
>100 days, p<0.0001 vs. MR; CD4
pres) or without anti-CD4 (n =
3, MST >100 days, p<0.001 vs. MR, CD4
abs), as seen by long-term
graft survival in all mice reconstituted with this population and
CD45RB
highCD4
+ cells. In contrast, all mice receiving
CD62L
+CD25
–CD4
+ cells and CD45RB
highCD4
+ cells rejected
their skin allografts with the same tempo as MR mice (Fig. 5B),
irrespective of previous culture in the presence (n = 5, MST =
Figure 2. In vitro and in vivo third party responses of CD4
pres. (A) CD4
pres were cultured at the indicated ratios with CD4
+ responder T cells (2  10
5)
from naive CBA mice and irradiated allogeneic splenocytes either from B10 mice or from third party (BALB/c) mice (5  10
5). Cells were cultured for
5 days and proliferation was measured by [
3H]-thymidine incorporation. Data are expressed as mean cpm  SD of triplicate cultures and are
representative of three independent experiments. (B) CBA.Rag
–/– mice were reconstituted with 10
5 CD45RB
highCD4
+ syngeneic T cells from naive
animals (MR mice) or together with 2  10
5 CD4
pres. The next day, mice received an allogeneic skin graft from B10, or third party BALB/c, mice. MR
mice acutely reject B10 (&, n = 7) and BALB/c skin grafts (&, n = 5). Co-transfer of 2  10
5 CD4
pres prevented rejection in four out of six mice receiving
B10 skin grafts (*, n = 6) whereas none of the BALB/c skin grafts were accepted (*, n = 7). Results were pooled from two independent experiments.
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pres) or absence (n = 5, MST =
22 days, p = 0.4 vs. MR for CD4
abs) of anti-CD4. In contrast,
CD62L
–CD25
intCD4
+ cells exhibited different regulatory capacity
depending on previous culture with (n = 5, MST >100 days,
p=0.055 vs. co-transfer of CD62L
+CD25
+ Tcells) or without anti-
CD4 (n = 6, MST = 22 days, p=0.1 vs. MR) (Fig. 5B). Thus,
CD62L
–CD25
intCD4
+ cells from CD4
pres cultures could prevent
skin graft rejection mediated by CD45RB
highCD4
+ cells in three
out of five mice. In contrast, none of the skin grafts survived
permanently when CD62L
–CD25
intCD4
+ cells from CD4
abs
cultures were co-transferred with CD45RB
highCD4
+ cells. These
data indicate that the anti-CD4 treatment results in phenotypic
differences(higherfrequencyofCD62LandCCR7positivecells)as
well as functional changes (in vivo regulatory capacity of
CD62L
–CD25
intCD4
+ cells) of allo-stimulated CD4
+ cells.
Interestingly, even 5  10
4 CD62L
+CD25
+CD4
+ cells from
CD4
pres were capable of regulating a skin transplant (data not
shown). In fact, 2  10
5 CD62L
+CD25
+CD4
+ cells were also able
to regulate rejection of a skin transplant from BALB/c mice (third
party) (n = 5, MST >100 days vs.MST >100 days, B10 skin grafts;
p>0.05, Fig. 5C), indicating that this population can exert
nonspecific regulation in vivo. Unfortunately, after expansion in
IL-2, it was not possible to test the regulatory properties of the
purified CD62L
+CD25
+CD4
+ cells in vivo due to the low numbers
ofcellsrecoveredfromthesecultures.Takentogether,theseresults
indicate that regulatory properties reside mainly in
CD62L
+CD25
+CD4
+ cells purified either from CD4
pres or CD4
pres
but also in CD62L
–CD25
intCD4
+ cells of CD4
pres cultures.
The highest percentage of FoxP3
+ cells can be found in
CD62L
+CD25
+CD4
+ and CCR7
+CD25
+CD4
+ cells
FoxP3 expression has been shown to characterize nTreg [38, 39]
and to be up-regulated in transgenic T cells cultured with bone
marrow dendritic cells and specific antigen [14]. For these reasons
we studied FoxP3 expression in subpopulations sorted from
CD4
pres. As shown in Fig. 6A, CD62L
+CD25
+CD4
+ cells exhibit
higher levels of FoxP3 (45.5%) than CD62L
–CD25
intCD4
+ (7.5%)
and CD62L
+CD25
–CD4
+ cells (0.9%) cells. These results are in
Figure 3. CD4
pres can be expanded in vitro but loose their potential to prevent graft rejection. (A) CD4
+ cells from naive CBA mice (2  10
5) were
cultured for 8 days in the presence of anti-CD4 and 5  10
5 allogeneic splenocytes from B10 mice. Percentage of cell recovery was calculated by
dividing the number of viable CD4
+ cells obtained after 8 days in culture by the numbers of CD4
+ cells at the start of the culture. Data represent the
mean  SD of more than 40 independent experiments. (B) Cells were harvested and 5  10
4 cells were restimulated for a further 7 days in the
presence of 25 U/mL of human IL-2 (expanded CD4
pres) and 5  10
5 irradiated allogeneic splenocytes from B10 mice. After restimulation, cells were
cultured with CFSE-stained CD4
+ responder T cells (2  10
5) from naive CBA mice and irradiated allogeneic B10 splenocytes (5  10
5). CFSE staining
was used to measure proliferation of the naive responder T cells after 7 days in culture. Numbers inside the histograms indicate the percentage of
cells that went through, at least, one round of division. The results shown are representative of four independent experiments. (C) CBA.Rag
–/– mice
were reconstituted with 10
5 CD45RB
highCD4
+ effector T cells alone or together with 2  10
5 IL-2 expanded CD4
pres. The next day, mice received an
allogeneic skin graft from B10 mice. MR mice acutely rejected B10 skin grafts (&, n = 8). Co-transfer of 2  10
5 IL-2 expanded CD4
pres did not prevent
rejection of B10 skin grafts (*, n =8 ) .
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these cell populations (Fig. 5B). When studying FoxP3 expression
in CCR7
+CD25
+CD4
+, CCR7
–CD25
intCD4
+ and CCR7
+CD25
–
CD4
+ cells from CD4
pres we found similar results (68.4, 33.3 and
0.4%, respectively, Fig. 6A). The same pattern was found for
subpopulations sorted from CD4
abs (data not shown). Taken
together, these results indicate that FoxP3
+ cells reside mainly in
the CD62L
+CD25
+CD4
+ or CCR7
+CD25
+CD4
+ subpopulation.
Despite this, CD62L
–CD25
intCD4
+ cells are also able to regulate
rejection of a skin allograft, which may give us the indication that
CD25 expression and other factors are more important for in vivo
regulation than CD62L. This assumption is further supported by
our observation that the CD62L
+CD25
+CD4
+ subpopulation can
be found in the draining lymph nodes and in the skin allograft and
does not prevent in vivo migration or proliferation of
CD45RB
highCD4
+ cells (data not shown).
Induced regulatory T cells can be differentiated from
CD25
–CD4
+ naive T cells.
We have also performed experiments using CD25
–CD4
+ cells
from naive CBA mice as responders in our anti-CD4 mAb-treated
mixedlymphocyte culture. Using our established protocol we were
able to generate 7.4% CD62L
+CD25
+Foxp3
+ cells after 8 days of
culture (Fig. 6B). In contrast, in control cultures 0.9% of the
CD25
–CD4
+ cells became CD62L
+CD25
+Foxp3
+. We also tested
their in vivo regulatory capacity. CBA.Rag
–/– mice were recon-
stituted with 10
5 CD45RB
highCD4
+ cells either alone or together
with 2  10
5 cells from unfractionated CD4
abs or CD4
pres cultures
setupusingCD25
–CD4
+Tcells.Thefollowingday,micereceiveda
B10 skin graft. Co-transfer of CD4
pres cells resulted in a
prolongation of skin graft survival (MST  SD: 24.8  3.9 days,
p=0.009) in comparison to recipients reconstituted with
CD45RB
highCD4
+ cells only (MST  SD: 16.5  3.5 days,
Fig. 6C). Whereas co-transfer of CD4
abs cells resulted in
accelerated skin graft rejection (MST  SD: 13  0 days). These
data clearly indicate that anti-CD4 mAb treatment during mixed
lymphocyte cultures facilitates both a selective expansion of initial
natural CD4
+CD25
+Foxp3
+ regulatory T cells but also a
differentiation of alloantigen-specific induced regulatory T cells,
which makes the anti-CD4 mAb treatment-based protocol even
more attractive for future clinical applications.
Discussion
Based on an established in vivo protocol known to select
alloantigen-reactive CD25
+CD4
+ regulatory T cells in vivo [16,
23], we investigated whether a similar strategy would result in the
selection of T cells with regulatory potential in vitro. Such an in
vitro approach is attractive, as the ex vivo generated regulatory
cells could be used throughout the post-transplant course to
enhance or sustain the unresponsive state achieved by the in vivo
therapy. In this system, mouse CD4
+ cells were purified and
cultured for 8 days with alloantigen in the form of allogeneic APC
and in the presence of a non-depleting anti-CD4 mAb. This in vitro
combination led to the selection, of CD4
+ cells, designated
CD4
pres, secreting high amounts of IL-10 and IFN-c (data not
shown) that are able to suppress the proliferation of naive
syngeneic T cells (Fig. 1A). More importantly, CD4
pres are able to
prevent rejection mediated by co-transfer of naive T cells (Fig. 1B
and C). This (lack of rejection) cannot be explained by an
activation induced anergy of CD4
pres, as rejection occurs in
CBA.Rag
–/–reconstitutedwithCD45RB
highCD4
+naiveTcellsonly.
Active regulation is required to prevent rejection mediated by
naive T cells. We believe that culture of naive CD4
+ cells with
alloantigen in the presence of anti-CD4 results in an enrichment
and selection of Treg.
It is generally thought that protocols generating Treg for
clinical application need to have the capacity to produce large
numbers of cells that retain their regulatory activity in vivo. When
we expanded CD4
pres further in vitro, we found that while the
expanded population retained potent suppressor function in vitro,
Figure 4. CD4
+ cells cultured for 8 days in the presence of anti-CD4
exhibit a higher percentage of CD62L and CCR7 cells. (A) CD4
+ cells from
naive CBA mice and CD4
pres before and after IL-2-mediated expansion
were stained with anti-CD4-PerCP, anti-CD62L-PE and anti-CD25-biotin
and streptavidin-APC. Plots of CD62L vs.CD25 expression gated on CD4
+
cells are shown. The data shown are representative of seven
independent experiments. (B) The expression of CCR7 is shown gated
in the CD4
+CD25
+ population. Numbers inside the histogram indicate
the percentage of cells that stained positive for CD4, CD25 and CCR7.
The data shown in (A) and (B) are representative of two independent
experiments.
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This loss of functional activity in vivo may result from the dramatic
decrease in the percentage of cells co-expressing CD25 and CD62L
and functional changes of the CD62L
–CD25
intCD4
+ population
after expansion with IL-2 (Fig. 4A). In vivo regulatory potential
resided mainly inthe CD62L
+CD25
+CD4
+subpopulation purified
from either the CD4
pres or CD4
abs cultures, but there was also
evidence for regulatory activity in CD62L
–CD25
intCD4
+ of CD4
pres
cultures(Fig.5B).ThepercentageofCD62L
+orCCR7
+cellsinthe
CD25
+CD4
+ population is higher in cultures in the presence of
anti-CD4 (Fig. 4B) and the anti-CD4 treatment results in
functional changes of CD62L
–CD25
intCD4
+cells, which again
demonstrates the important role of this antibody for the in vitro
enrichment and selection of Treg.
CD62L
+CD25
+CD4
+ cells from CD4
pres cultures exhibited
higher percentages of FoxP3 expression than either
CD62L
+CD25
–CD4
+ or CD62L
+CD25
intCD4
+ cells (Fig. 6A).
The percentage of FoxP3
+ cells found in CD62L
–CD25
intCD4
+
varied between experiments, but it was always lower than that
found in CD62L
+CD25
+CD4
+ cells. In vivo, CD62L
+CD25
+CD4
+
cells from CD4
pres cultures were detected both in the draining
lymph node and in the skin graft 7 days after transplantation, but
were not detected in the spleen of reconstituted CBA.Rag
–/– mice
(data not shown). These results are in accordance with
Figure 5. In vivo regulation is enriched within the CD62L
+CD25
+CD4
+ subpopulation. (A) CD4
pres or CD4
abs were fractionated into three
subpopulations based on surface expression of CD25 and CD62L. (B) CBA.Rag
–/– mice were reconstituted with 10
5 CD45RB
highCD4
+ effector T cells
alone (control= MR mice; &, n = 9) or together with 2  10
5 of the following purified cell populations: CD62L
+CD25
+CD4
+ cells fromCD4
pres(*; n = 11),
CD62L
–CD25
intCD4
+ cells from CD4
pres (*; n = 5), CD62L
+CD25
–CD4
+ cells from CD4
pres (&; n = 5), CD62L
+CD25
+CD4
+ cells from CD4
abs (*; n =5 ) ,
CD62L
–CD25
intCD4
+fromCD4
abs(*;n =6) and CD62L
+CD25
–CD4
+cells fromCD4
pres(&;n = 5).The next day themice receivedan allogeneic skingraft
from B10 mice. These results were pooled from four independent experiments. (C) CBA.Rag
–/– mice were reconstituted with 10
5 CD45RB
highCD4
+
syngeneic T cells from naive animals (MR mice) or together with CD62L
+CD25
+CD4
+ cells from CD4
pres cultures. The next day mice received an
allogeneic skin graft from B10, or third party BALB/c, mice. MR mice acutely reject B10 (&; n = 7) and BALB/c skin grafts (&; n = 5). Co-transfer of
CD62L
+CD25
+CD4
+ cells prevented rejection in five out of five mice receiving B10 skin grafts (*; n = 5) and three out of five of the mice receiving
BALB/c skin grafts (*; n = 5). Results were pooled from three independent experiments.
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CD62L
+CD25
+CD4
+ cells expressing CCR7 are able to delay
diabetes transfer in NOD mice [36]. Expression of CD62L was also
found to be important for the localization of regulatory cells into
secondary lymphoid organs in models of cardiac transplantation
[33] and graft-versus-host disease [40]. Furthermore, recently it
was shown that CCR7 is required for the in vivo function of
CD25
+CD4
+ regulatory T cells [41]. Thus, we can speculate that
CD62L and CCR7 expression is required for regulatory cells to
migrate into the lymph nodes and regulate the priming of naive
T cells, but other factors induced by the anti-CD4 treatment are
also important.
To increase the amount of antigen-specific regulatory T cells
for in vivocell therapy,a protocolaimed ongeneratingTregshould
alsoenabledifferentiationof inducedTregfromCD25
–CD4
+naive
precursors. It has been shown that polyclonal stimulation of naive
T cells in the presence of TGF-b results in the differentiation of
induced Treg [42, 43]. Our results demonstrate that also
stimulation of CD25
–CD4
+ naive T cells with alloantigen in the
presence of the non-depleting anti-CD4 antibody YTS177 enables
differentiation of CD25
+Foxp3
+ induced Treg with high regula-
tory potential in vivo.
The ultimate challenge for our in vitro generation protocol
would be to test the regulatory capacity of CD4pres cells upon
transfer into fully immunocompetent recipients. Indeed, we are
currently performing experiments in which we transfer CD4pres
cells into otherwise untreated na ve C57BL/6 mice receiving an
allograft.
Figure6.Foxp3expressionandinvivoregulatorycapacitywhenusingCD25
–CD4
+naiveTcellsasresponders.(A)CD4
preswerestainedwithanti-CD4-
FITC, anti-CD62L-PE oranti-CCR7-PE,anti-CD25-biotin and streptavidin-CyChromeand FoxP3-APC.The expressionof FoxP3 is shown aftergating in
theindicated subpopulationsfromCD4
pres.NumbersinsidethehistogramindicatethepercentageofcellsthatstainedpositiveforCD4,CD25,CD62L
or CCR7 and FoxP3. The data shown are representative of two independent experiments. (B) Foxp3 expression gated on CD4
+CD25
+ cells of CD4
pres
and CD4
abs cultures of CD25
–CD4
+ naive T cells. (C) CBA.Rag
–/– mice were reconstituted with 10
5 CD45RB
highCD4
+ effector T cells from naive animals
(control = MR mice) or together with 2  10
5 CD4
pres or CD4
abs. MR mice acutely reject B10 skin grafts (&, n = 6; MST = 16.5  3.5 days). Co-transfer of
2  10
5 CD4
pres prolonged skin graft survival (*, n = 5; MST = 24.8  3.9 days) whereas co-transfer of 2  10
5 CD4
abs resulted in accelerated rejection
(~, n = 3; MST = 13.0  0.0 days).
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as stringent strain combinations and most likely in clinical
transplantation we need powerful protocols for in vitro generation
and differentiation of antigen specific regulatory T cells. Our
protocol presented here may be one approach to generate such
potent Tregs.
Recently, Golshayan et al. [44] have presented a protocol of
selecting and expanding Treg with indirect allospecificity for a
single MHC class I antigen (H2K
b) from a pool of naturally
occurring Treg using H2K
b peptide-pulsed immature dendritic
cells. The expanded Treg lines could regulate indirect allo-
responses of effector CD4
+ cells in vivo. In contrast, the expanded
Treg could not inhibit direct pathway alloresponses, such that
C57BL/6 skin transplants were rejected with the same kinetic as in
control mice [44]. These data indicate that Treg with a broader
spectrum of alloreactivty is most likely required to control
rejection of a fully allogeneic graft. The protocol for generating
Treg reported here is aimed at selecting Treg controlling direct
pathway immune responses and therefore complements the
findings made by Golshayan et al. [44].
The underlying mechanism by which anti-CD4 antibody
treatment induces the enrichment/selection of Treg in vitro
remains to be investigated. CD4 is an important accessory and
costimulatory molecule that augments the signal received by the
TCR complex and helps in the activation of the T cells [45].
Blockade of this interaction using anti-CD4 antibodies increases
the threshold of activation through the TCR, so that, under these
conditions, only cells with high affinity have the capacity to be
activated and proliferate [46]. These cells with high affinity/
specificity TCR could be identical with cells that manifest
regulatory activity in this study. Indeed, autoreactive CD25
+CD4
+
regulatory cells can be generated in the thymus by interactions
with a single self-peptide. Selection of these cells appears to
require a TCR with high affinity for a self peptide as thymocytes
with low-affinity TCR do not undergo selection into this pathway
[47]. Furthermore, reduced or blocking levels of CD4 expression,
can convert T cell responses from stimulatory to inhibitory [48].
We can speculate that using the protocol described here, T cell
activation has purposefully become more difficult and only a small
percentage of cells can undergo activation and proliferation
(regulatory population), while cells that do not receive any signals
eventually die by apoptosis (these include the effector popula-
tion). Indeed, in our previous studies we could show that anti-CD4
mAb-treated allo-reactive T cells are characterised by a relative
resistance to activation-induced cell death (AICD) [49]. Thus, we
can conclude that anti-CD4 mAb treatment of allo-reactive Tcells
facilitates the expansion and differentiation of antigen.specific
Treg, which are characterised by a relative resistance to AICD,
whereas effector T cells dye by apoptosis. Alternatively, the anti-
CD4 antibody may directly deliver a negative signal into the Tcells
[50]andtherebydrivetheselectionofapopulation ofTreginstead
ofselecting itfromapre-existingpool. Interestingly,arecentstudy
performed by McFadden et al. [51] has revealed that stimulation
with the CD4 ligand IL-16 results in enhanced migration and
de novo induction of a regulatory population of CD25
+CTLA4
+
Foxp3
+cells.ItislikelythatTCRaffinityandCD4expressionlevels
at the cell surface both play equal roles in our protocol. Following
this line of thinking, we believe that it may be possible to develop
protocols, targeting one or more accessory or costimulatory
molecules [11], to generate stringent culture conditions in which
only a specific T cell population (regulatory population) can be
selected [20].
Our findings may help to understand the mechanisms
underlying the function of Treg in vitro and in vivo, which will
enable its use the cells for therapeutic strategies in vivo. This
protocol, stimulating T cells with alloantigen-presenting cells in
the presence of anti-CD4, provides a powerful, simple and fast
method of obtaining cells ex vivo with strong regulatory potential
but also illustrates the immense tolerogenic and therapeutic
potential of non-depleting anti-CD4 antibodies.
Mice
CBA.Ca (CBA, H2
k), C57BL/10 (B10, H2
b), BALB/c (H2
d), CD52-
transgenic CP1-CBA.Ca (H-2
k), and CBA.Rag 1
–/– (H2
k) were bred
andhousedintheBiomedicalServicesfacilityattheJohnRadcliffe
Hospital (Oxford, UK) in accordance with the Animals (Scientific
Procedure) Act 1986 of the UK. Sex-matched mice aged
6–12 weeks were used in all experiments.
Reagents and monoclonal antibodies
The following reagents were used for in vitro assays and flow
cytometry. Thehybridomas YTS 169.4.2(anti-CD8) and YTS 177.9
(“YTS 177”, anti-CD4) were kindly provided by Professor Herman
Waldmann (Sir William Dunn School of Pathology, Oxford, UK).
TIB120 (anti-class II) was obtained from American Type Culture
Collection (ATCC) Manassas, VA). RM4–5 (anti-CD4)-cychrome,
16A (anti-CD45RB)-PE, MEL-14 (anti-CD62L)-PE, 7D4 (anti-
CD25)-biotin and streptavidin-allophycocyanin were from Phar-
Mingen (San Diego, CA). 4B12 (anti-CCR7)-PE and FJK-16s (anti-
FoxP3)-APC were from eBioscience (San Diego, CA). CFSE was
from Molecular Probes (OR).
Cell preparation and purification
Purification of T cell subpopulations
Single-cell suspensions from spleen and lymph nodes of naive CBA
mice were prepared by forcing the organs through a 70-lm nylon
mesh. After erythrocyte removal by hypotonic lysis, cell suspen-
sions were incubated with YTS169 (anti-CD8, 200 lg/mL) and
TIB120 (anti-class II, 100 lg/mL) at 2  10
8 cells/mL. Cell
suspension was incubated with sheep anti-rat-coated Dynabeads
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– and MHC class II
– cells were
isolated by magnetic separation, the CD4
+-enriched population
resuspended and stained for CD4 and CD45RB. CD45RB
highCD4
+
cells with 99% purity were obtained by cell sorting using a
FACSVantage (Becton Dickinson, San Jose, CA).
Cell culture
RPMI 1640 culture medium was supplemented with 10% FBS,
2 mM L-Glutamine, 0.5 mM 2-mercaptoethanol, and 100 U/mL
each penicillin, streptomycin and kanamycin. Irradiated
(3600 rad) allogeneic total splenocytes from B10 mice were used
as APC (B10 APC). Purified CD4
+ cells (mouse CD4
+ isolation kit
Miltenyi Biotec, Bergisch-Gladbach, Germany) from naive CBA
mice were cultured at 2  10
5 cells/well in the presence (CD4
pres)
orabsence(CD4
abs)of5lg/mLofYTS177anti-CD4mAbtogether
with 5 10
5 APC. Cells were cultured for 8 days,harvested, debris
separated from live cells by gradient centrifugation using
lymphoprep medium (Axis-Shield PoC AS, Oslo, Norway) and
used in a regulation assay. In some experiments, CD4
+ cells
precultured with anti-CD4 (5  10
4) were restimulated with 5 
10
5 APC in the presence of 25 U/mL human IL-2 (Roche)
(expanded CD4
pres). Proliferation of naive responders was
assessed by [
3H]thymidine (0.5 lCi) incorporation or CFSE
dilution after 5 or 7 days in culture, respectively.
Cell reconstitution and skin transplantation
CBA.Rag 1
–/– mice were reconstituted intravenously with
syngeneic fractionated T cells. CD45RB
highCD4
+ cells (10
5)
purified from naive CBA mice were used routinely to elicit
rejection of an allogeneic skin graft [16]. The day after
reconstitution, all mice received a B10 skin graft as previously
described [16]. Graft rejection was defined as complete destruc-
tion of the skin graft.
Flow cytometric analysis
Cell cultures were incubated with the appropriate antibodies. All
incubations were carried out for 20 min at 4
C. Data were
acquired using a FACSort (Becton Dickinson, San Jose, CA) and
analysed using CellQuest software package (Becton Dickinson).
Intracellular staining for FoxP3 studies was performed according
to the manufacturer's instructions.
Statistics
The Log Rank Method was used to compare allograft survival
between groups using GraphPad Prism version 3.00 for Windows
(GraphPad Software, San Diego, CA).
The data were analysed using a two-tailed unpaired Student's
t-test. Results are given as the mean  SD. p-values of <0.05 were
considered significant.
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